Bone marrow-derived mononuclear stem cells in the treatment of retinal degenerations  

作　　者：Diego García-Ayuso Johnny Di Pierdomenico David García-Bernal Manuel Vidal-Sanz María P.Villegas-Pérez 

机构地区：[1]Departamento de Oftalmología,Facultad de Medicina,Universidad de Murcia,Campus de Ciencias de la salud,Murcia,Spain [2]Instituto Murciano de Investigación Biosanitaria Hospital Virgen de la Arrixaca(IMIB-Virgen de la Arrixaca),Murcia,Spain [3]Servicio de Hematología,Hospital Clínico Universitario Virgen de la Arrixaca,Murcia,Spain

出　　处：《Neural Regeneration Research》2022年第9期1937-1944,共8页中国神经再生研究（英文版）

基　　金：by Fundación Lucha contra la Ceguera(FUNDALUCE)to MPVP;Fundación Robles Chillida to DGA;Fundación Séneca,Agencia de Ciencia y Tecnología Región de Murcia(19881/GERM/15 to MVS);the Spanish Ministry of Science and Innovation,Instituto de Salud Carlos III,Fondo Europeo de Desarrollo Regional“Una Manera de Hacer Europa”(SAF2015-67643-P to MVS,PI19/00203 to MPVP and DGA,RD16/0008/0026 to MPVP,RED2018-102499-T to MVS).

摘　　要：Retinal degenerative diseases affecting the outer retina in its many forms(inherited,acquired or induced)are characterized by photoreceptor loss,and represent currently a leading cause of irreversible vision loss in the world.At present,there are very few treatments capable of preventing,recovering or reversing photoreceptor degeneration or the secondary retinal remodeling,which follows photoreceptor loss and can also cause the death of other retinal cells.Thus,these diseases are nowadays one of the greatest challenges in the field of ophthalmological research.Bone marrow derived-mononuclear stem cell transplantation has shown promising results for the treatment of photoreceptor degenerations.These cells may have the potential to slow down photoreceptor loss,and therefore should be applied in the early stages of photoreceptor degenerations.Furthermore,because of their possible paracrine effects,they may have a wide range of clinical applications,since they can potentially impact on several retinal cell types at once and photoreceptor degenerations can involve different cells and/or begin in one cell type and then affect adjacent cells.The intraocular injection of bone marrow derived-mononuclear stem cells also enhances the outcomes of other treatments aimed to protect photoreceptors.Therefore,it is likely that future investigations may combine bone marrow derived-mononuclear stem cell therapy with other systemic or intraocular treatments to obtain greater therapeutic effects in degenerative retinal diseases.

关 键 词：age-related macular degeneration bone marrow stem cells intravitreal injection macroglia MICROGLIA photoreceptor degeneration retinal ganglion cells retinitis pigmentosa subretinal injection TRANSPLANT 

分 类 号：R774.13[医药卫生—眼科]